Astellas Pharma, Inc. reported that the U.S Food and Drug Administration (FDA) had approved a supplemental New Drug Application (sNDA) for the use of mirabegron in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder with symptoms of urge incontinence, urgency, and frequency.
AbbVie Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for BOTOX the only exclusive neurotoxic, which provides a novel therapeutic alternative for the treatment of neurogenic detrusor overactivity in pediatric patients who are not well controlled by anticholinergic drugs. Further, BOTOX is one of the most extensively researched drugs in the world which is injected into muscles and also used to treat overactive bladder symptoms such as a strong need to urinate with urge urinary incontinence, urgency, and urinating frequently.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4868
Published Date: Jul 27, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Growing number of pregnancies and the growing inclination toward minimally invasive procedures are the major factors driving the growth of the market.
The market size of overactive bladder treatment is anticipated to attain a CAGR of 6.60% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are Pfizer, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Endo International Plc., Johnson & Johnson Private Limited, India Medtronic Private Limited, Boston Scientific Corporation.
The neurostimulation segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.